117 related articles for article (PubMed ID: 21108534)
1. Cost of illness in patients with metastatic colorectal cancer.
Song X; Zhao Z; Barber B; Gregory C; Cao Z; Gao S
J Med Econ; 2011; 14(1):1-9. PubMed ID: 21108534
[TBL] [Abstract][Full Text] [Related]
2. Estimating costs of care for patients with newly diagnosed metastatic colorectal cancer.
Paramore LC; Thomas SK; Knopf KB; Cragin LS; Fraeman KH
Clin Colorectal Cancer; 2006 May; 6(1):52-8. PubMed ID: 16796792
[TBL] [Abstract][Full Text] [Related]
3. Comparison of approaches for estimating incidence costs of care for colorectal cancer patients.
Yabroff KR; Warren JL; Schrag D; Mariotto A; Meekins A; Topor M; Brown ML
Med Care; 2009 Jul; 47(7 Suppl 1):S56-63. PubMed ID: 19536010
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy in the initial treatment of newly diagnosed cancer patients: utilization trend and cost projections for non-Hodgkin's lymphoma, metastatic breast cancer, and metastatic colorectal cancer.
Shih YC; Elting LS; Pavluck AL; Stewart A; Halpern MT
Cancer Invest; 2010 Jan; 28(1):46-53. PubMed ID: 19995227
[TBL] [Abstract][Full Text] [Related]
5. Cost-minimisation analysis in first-line treatment of metastatic colorectal cancer in France: XELOX versus FOLFOX-6.
Perrocheau G; Bennouna J; Ducreux M; Hebbar M; Ychou M; Lledo G; Conroy T; Dominguez S; Faroux R; Florentin V; Douillard JY
Oncology; 2010; 79(3-4):174-80. PubMed ID: 21358204
[TBL] [Abstract][Full Text] [Related]
6. Characterizing medical care by disease phase in metastatic colorectal cancer.
Song X; Zhao Z; Barber B; Gregory C; Schutt D; Gao S
Am J Manag Care; 2011 May; 17 Suppl 5 Developing():SP20-5. PubMed ID: 21711074
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of first-line chemotherapies in metastatic colorectal cancer. Results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 randomized trial.
Borget I; Aupérin A; Pignon JP; Abbas M; Bouché O; Mousseau M; Raoul JL; Bedenne L; Cassan P; Clavero-Fabri MC; Stremsdoerfer N; Nasca S; Queuniet AM; Ducreux M;
Oncology; 2006; 71(1-2):40-8. PubMed ID: 17344670
[TBL] [Abstract][Full Text] [Related]
8. The value of new chemotherapeutic agents for metastatic colorectal cancer.
Howard DH; Kauh J; Lipscomb J
Arch Intern Med; 2010 Mar; 170(6):537-42. PubMed ID: 20233802
[TBL] [Abstract][Full Text] [Related]
9. [Assessment of the cost of first line chemotherapy in metastatic colorectal cancer. Preliminary results in the FFCD 9601 trial].
Locher C; Auperin A; Boige V; Alzieu L; Pignon JP; Abbas M; Ducreux M
Gastroenterol Clin Biol; 2001; 25(8-9):749-54. PubMed ID: 11598535
[TBL] [Abstract][Full Text] [Related]
10. Lifetime cancer-attributable cost of care for long term survivors of colorectal cancer.
Ramsey SD; Berry K; Etzioni R
Am J Gastroenterol; 2002 Feb; 97(2):440-5. PubMed ID: 11866285
[TBL] [Abstract][Full Text] [Related]
11. Cost of care for elderly cancer patients in the United States.
Yabroff KR; Lamont EB; Mariotto A; Warren JL; Topor M; Meekins A; Brown ML
J Natl Cancer Inst; 2008 May; 100(9):630-41. PubMed ID: 18445825
[TBL] [Abstract][Full Text] [Related]
12. The relevance of unrelated costs internal and external to the healthcare sector to the outcome of a cost-comparison analysis of secondary prevention: the case of general colorectal cancer screening in the German population.
Tscheulin DK; Drevs F
Eur J Health Econ; 2010 Apr; 11(2):141-50. PubMed ID: 19449159
[TBL] [Abstract][Full Text] [Related]
13. Economic impact of simplified de Gramont regimen in first-line therapy in metastatic colorectal cancer.
Limat S; Bracco-Nolin CH; Legat-Fagnoni C; Chaigneau L; Stein U; Huchet B; Pivot X; Woronoff-Lemsi MC
Eur J Health Econ; 2006 Jun; 7(2):107-13. PubMed ID: 16474968
[TBL] [Abstract][Full Text] [Related]
14. The impact of including future medical care costs when estimating the costs attributable to a disease: a colorectal cancer case study.
Etzioni R; Ramsey SD; Berry K; Brown M
Health Econ; 2001 Apr; 10(3):245-56. PubMed ID: 11288190
[TBL] [Abstract][Full Text] [Related]
15. The development of a value based pricing index for new drugs in metastatic colorectal cancer.
Dranitsaris G; Truter I; Lubbe MS
Eur J Cancer; 2011 Jun; 47(9):1299-304. PubMed ID: 21493060
[TBL] [Abstract][Full Text] [Related]
16. Costs and cost effectiveness of a health care provider-directed intervention to promote colorectal cancer screening among Veterans.
Wolf MS; Fitzner KA; Powell EF; McCaffrey KR; Pickard AS; McKoy JM; Lindenberg J; Schumock GT; Carson KR; Ferreira MR; Dolan NC; Bennett CL
J Clin Oncol; 2005 Dec; 23(34):8877-83. PubMed ID: 16314648
[TBL] [Abstract][Full Text] [Related]
17. Estimating the cost of cancer care in the United States: a work very much in progress.
Lipscomb J
J Natl Cancer Inst; 2008 May; 100(9):607-10. PubMed ID: 18445816
[No Abstract] [Full Text] [Related]
18. Cost of care of colorectal cancers according to health care patterns and stage at diagnosis in France.
Clerc L; Jooste V; Lejeune C; Schmitt B; Arveux P; Quantin C; Faivre J; Bouvier AM
Eur J Health Econ; 2008 Nov; 9(4):361-7. PubMed ID: 18030510
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of computerized tomographic colonography versus colonoscopy for colorectal cancer screening.
Heitman SJ; Manns BJ; Hilsden RJ; Fong A; Dean S; Romagnuolo J
CMAJ; 2005 Oct; 173(8):877-81. PubMed ID: 16217110
[TBL] [Abstract][Full Text] [Related]
20. Lifetime and treatment-phase costs associated with colorectal cancer: evidence from SEER-Medicare data.
Lang K; Lines LM; Lee DW; Korn JR; Earle CC; Menzin J
Clin Gastroenterol Hepatol; 2009 Feb; 7(2):198-204. PubMed ID: 18849013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
